Home › Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration
 

Keywords :   


Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration

2014-02-05 07:17:03| drugdiscoveryonline News Articles

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, recently announced that it has elected to retain the United States development and commercial rights to the isocitratedehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism

Tags: rights under development program

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.06Wrap sold in WH Smith recalled over E. coli fears
17.06Atlantic Tropical Weather Outlook
17.06Eastern North Pacific Tropical Weather Outlook
17.06Pixar's Inside Out 2 sees record opening weekend
17.06Atlantic Tropical Weather Outlook
17.06Eastern North Pacific Tropical Weather Outlook
17.06Too much of a good thing? Spain's green energy can exceed demand
16.06Eastern North Pacific Tropical Weather Outlook
More »